Targeted drug crizotinib tested against hard-to-treat cancers with MET gene change
NCT ID NCT06357975
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug crizotinib in 44 patients with advanced solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib works by blocking enzymes that help cancer cells grow and spread. The main goal is to see if the drug can shrink or slow the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Crizotinib (a targeted drug that blocks enzymes cancer cells need to grow)
- What this could lead to
- If it works, this could provide a new treatment option for patients with advanced cancers that have a specific genetic change (MET amplification).
- What could go wrong
- This is a small, early-phase trial (44 patients) with no control group, so results may not apply broadly. Crizotinib can cause side effects like nausea, vision problems, and liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma